Prostate cancer is a common malignancy of elderly, and with aging of the population the need is growing for therapies suitable for this age group. Lutetium-177-PSMA (Lu-PSMA), a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA), enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer (mCRPC).